187 related articles for article (PubMed ID: 31574418)
1. Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC).
Rivin Del Campo E; Matzinger O; Haustermans K; Peiffert D; Glynne-Jones R; Winter KA; Konski AA; Ajani JA; Bosset JF; Hannoun-Levi JM; Puyraveau M; Chakravarthy AB; Meadows H; Northover J; Collette L; Christiaens M; Maingon P
Eur J Cancer; 2019 Nov; 121():130-143. PubMed ID: 31574418
[TBL] [Abstract][Full Text] [Related]
2. "Mind the gap"--the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I).
Glynne-Jones R; Sebag-Montefiore D; Adams R; McDonald A; Gollins S; James R; Northover JM; Meadows HM; Jitlal M;
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1488-94. PubMed ID: 20934265
[TBL] [Abstract][Full Text] [Related]
3. [Concurrent radiochemotherapy with 5-FU/mitomycin remains standard treatment for anal carcinoma. Long-term results of the phase III RTOG 98-11 trial].
Nieder C
Strahlenther Onkol; 2013 Jun; 189(6):512-3. PubMed ID: 23609134
[No Abstract] [Full Text] [Related]
4. Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study.
Wo JY; Plastaras JP; Metz JM; Jiang W; Yeap BY; Drapek LC; Adams J; Baglini C; Ryan DP; Murphy JE; Parikh AR; Allen JN; Clark JW; Blaszkowsky LS; DeLaney TF; Ben-Josef E; Hong TS
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):90-95. PubMed ID: 31128146
[TBL] [Abstract][Full Text] [Related]
5. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Gunderson LL; Winter KA; Ajani JA; Pedersen JE; Moughan J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
J Clin Oncol; 2012 Dec; 30(35):4344-51. PubMed ID: 23150707
[TBL] [Abstract][Full Text] [Related]
6. Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C.
White EC; Goldman K; Aleshin A; Lien WW; Rao AR
Radiother Oncol; 2015 Nov; 117(2):240-5. PubMed ID: 26347494
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292).
Chakravarthy AB; Catalano PJ; Martenson JA; Mondschein JK; Wagner H; Mansour EG; Talamonti MS; Benson AB
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e607-13. PubMed ID: 21514072
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a 36 Gy elective node irradiation dose in anal cancer.
Lépinoy A; Lescut N; Puyraveau M; Caubet M; Boustani J; Lakkis Z; Fantoli M; Buffet-Miny J; Kim S; Bednarek C; Maingon P; Créhange G; Bosset JF
Radiother Oncol; 2015 Aug; 116(2):197-201. PubMed ID: 26277433
[TBL] [Abstract][Full Text] [Related]
10. Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.
Thind G; Johal B; Follwell M; Kennecke HF
Radiat Oncol; 2014 May; 9():124. PubMed ID: 24885554
[TBL] [Abstract][Full Text] [Related]
11. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D
Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724
[TBL] [Abstract][Full Text] [Related]
12. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Glynne-Jones R; Meadows H; Wan S; Gollins S; Leslie M; Levine E; McDonald AC; Myint S; Samuel L; Sebag-Montefiore D;
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):119-26. PubMed ID: 18472366
[TBL] [Abstract][Full Text] [Related]
13. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
Kachnic LA; Winter K; Myerson RJ; Goodyear MD; Willins J; Esthappan J; Haddock MG; Rotman M; Parikh PJ; Safran H; Willett CG
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):27-33. PubMed ID: 23154075
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529.
Olsen JR; Moughan J; Myerson R; Abitbol A; Doncals DE; Johnson D; Schefter TE; Chen Y; Fisher B; Michalski J; Narayan S; Chang A; Crane CH; Kachnic L
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):400-408. PubMed ID: 28463160
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
[TBL] [Abstract][Full Text] [Related]
16. Revisiting the Radical Radiotherapy-Radiochemotherapy Results in Anal Canal Cancers: (TROD Gastrointestinal Group Study 02-005).
Gul SK; Tepetam H; Yildiz F; Er I; Oksuz DC; Parvizi M; Ozden AS; Alicikus ZA; Sari SY; Alomari O; Gorken IB
Clin Colorectal Cancer; 2023 Sep; 22(3):318-326. PubMed ID: 37336706
[TBL] [Abstract][Full Text] [Related]
17. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
Ajani JA; Winter KA; Gunderson LL; Pedersen J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett C
JAMA; 2008 Apr; 299(16):1914-21. PubMed ID: 18430910
[TBL] [Abstract][Full Text] [Related]
18. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.
Glynne-Jones R; Sebag-Montefiore D; Meadows HM; Cunningham D; Begum R; Adab F; Benstead K; Harte RJ; Stewart J; Beare S; Hackshaw A; Kadalayil L;
Lancet Oncol; 2017 Mar; 18(3):347-356. PubMed ID: 28209296
[TBL] [Abstract][Full Text] [Related]
19. [The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients].
Grabenbauer GG; Panzer M; Hültenschmidt B; Döker R; Huber K; Kuhne-Velte HJ; Hutter M; Rühl U; Budach V; Wendt T
Strahlenther Onkol; 1994 Jul; 170(7):391-9. PubMed ID: 8052938
[TBL] [Abstract][Full Text] [Related]
20. Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
Ferrigno R; Nakamura RA; Dos Santos Novaes PE; Pellizzon AC; Maia MA; Fogarolli RC; Salvajoli JV; Filho WJ; Lopes A
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1136-42. PubMed ID: 15752894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
